Table 3 Ongoing phase 1 (or pilot) clinical trials of combination approaches in sarcoma
Targeted antiangiogenic agent | Chemotherapy regimen | Tumor type | NCT |
|---|---|---|---|
Bevacizumab | Doxorubicin/temsirolimus | Advanced solid tumors, including sarcoma | 00761644 |
Bevacizumab | Doxorubicin | Advanced Kaposi sarcoma | 00923936 |
Bevacizumab | Gemcitabine/docetaxel/valproic acid | Advanced sarcoma | 01106872 |
Bevacizumab | Gemcitabine/paclitaxel | Advanced solid tumors, including sarcoma | 01113476 |
Bevacizumab | Irinotecan/temozolomide + standard alkylator-based chemotherapy | Newly diagnosed DSRCT | 01189643 |
Bevacizumab | Metronomic doxorubicin + radiation | Resectable STS | 01746238 |
Bevacizumab | Metronomic cyclophosphamide/valproic acid/temsirolimus | Advanced solid tumors, including sarcoma | 02446431 |
Pazopanib | Gemcitabine | Advanced leiomyosarcoma | 01442662 |
Pazopanib | Docetaxel/gemcitabine | Operable STS | 01719302 |
Pazopanib | Metronomic topotecan | Advanced solid tumors, including sarcoma | 02303028 |